Clinical Trials - The Effect of Naloxegol in Cancer Opioid-Induced Constipation - Constipation

Opioid-induced constipation (OIC) is a common symptom in patients. Naloxegol has been proved to be helpful in relieving the pain caused by cancer. The purpose of this study is to compare the effect of naloxegol versus the patient’s usual care in treating opioid-induced constipation, as well as the effect on the patient’s quality of life and how much pain is experienced.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Single Center, Pilot Feasibility Study to Evaluate Naloxegol for Opioid-Induced Constipation in Cancer Patients
Study Start Date : May 2016
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2021

Contacts

Contact: Chelsea Hagmann chagmann@ucsd.edu
ClinicalTrials.gov Identifier: NCT02745353

For enrollment please visit www.clinicaltrials.gov.

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.